Bivalirudin hepatic or renal clearance
WebThe majority of patients with acute coronary syndromes have renal impairment from either the aging process or from underlying disease, such as nephrosclerosis or diabetes. For example, in the phase 3 studies of bivalirudin use in PTCA, only 25% of patients had normal renal function: 46% had mild ren … WebSep 15, 2024 · The clearance of bivalirudin was reduced approximately 20% in patients with moderate and severe renal impairment and was reduced approximately 80% in …
Bivalirudin hepatic or renal clearance
Did you know?
WebBivalirudin concentration may be affected by drug interactions, liver, and renal disease. Marked presence of hemolysis or bilirubin in the sample could falsely decrease … WebBackground: These studies were conducted to determine whether bivalirudin clearance and pharmacodynamics are dependent on dose, renal function, or gender. Methods: Two studies were performed. The first comprised 25 patients who were undergoing percutaneous coronary intervention-8 with normal renal function, 11 with mild renal impairment, and 6 …
WebNov 16, 2005 · Argatroban is metabolized in the liver and should be used with caution in patients with hepatic insufficiency. Bivalirudin is approved for use in percutaneous coronary intervention and is under study for use in patients with HIT undergoing cardiopulmonary bypass. Bivalirudin has a short half-life (25 min) and is 20% … Webexcretion does not depend on renal function [4]. Bivalirudin is a 20 amino-acids hirudin-analogue with a molecular mass of 2’180 Da and a half-life of ~25 minutes; it is eliminated by proteolysis and for ~20% by renal clearance [5]. Both bind human thrombin reversibly, argatroban with an inhibitory constant of 40 nM and bivalirudin 2 nM [4,5]. In
WebPopulation pharmacokinetics and pharmacodynamics of bivalirudin in young healthy Chinese volunteers WebTherefore, severe renal impairment and hepatic impairment both cause a reduction in its rate of clearance [81,82]. From: Meyler's Side Effects of Drugs (Sixteenth Edition), 2016. ... Patients with moderate and severe renal impairment have reductions in bivalirudin clearance. An analyses of data for 4312 patients with unstable angina showed ...
WebJun 1, 2024 · Bivalirudin does not bind to plasma proteins (other than thrombin) or to red blood cells. Elimination. Bivalirudin has a half-life of 25 minutes in PTCA patients with normal renal function. The total body clearance of Bivalirudin in PTCA patients with normal renal function is 3.4 mL/min/kg. Metabolism. Bivalirudin is metabolized by …
WebOct 17, 2024 · Bivalirudin is a direct thrombin inhibitor that may require lower doses to reach therapeutic targets in patients receiving renal replacement therapy . While a small … armagnac dan murphyWebJun 19, 2024 · Clearance is reduced by 21% in moderate and severe renal impairment and by 70% in dialysis patients. Use: Labeled Indications Percutaneous coronary … balrampur to kathmanduWebBivalirudin is cleared from plasma by a combination of renal mechanisms and proteolytic cleavage Half-life: -Normal renal function (≥ 90 mL/min) = 25 minutes -Mild renal … arma global tampaWebJul 1, 2002 · Bivalirudin is cleared from plasma by a combination of renal mechanisms and proteolytic cleavage, with a half-life of 25 min in patients with normal renal function [27]. The clearance of ... armag kentuckyWebArgatroban is a synthetic, nonpeptide small molecular weight (~500 Da) L-arginine derivative that reversibly inhibits thrombin by means of univalent binding to the active site (exosite 3; fig. 1A). 6 Argatroban is … balram roupasWebBivalirudin concentration may be affected by drug interactions, liver, and renal disease. Marked presence of hemolysis or bilirubin in the sample could falsely decrease … balram singh vs kelo deviWebJun 19, 2024 · Includes Bivalirudin indications, dosage/administration, pharmacology, mechanism/onset/duration of action, half-life, dosage forms, interactions, warnings, adverse reactions, off-label uses and more. ... Renal Function Impairment. Clearance is reduced by 21% in moderate and severe renal impairment and by 70% in dialysis patients. armagi srl